It leads to nerve damage and neurological issues
Strengthened skin resilience
It is a multinational pharmaceutical company that specialises in developing, manufacturing, and marketing a broad range of products, including generics, injectables, and biotherapeutics
It is not a hormone, not a peptide hormone analog, and not approved for any human therapeutic use by any regulatory authority as of 2025
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)